

#5



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE
STATEMENT**

Docket Number:
1662/54903

Application Number
10/000,428

Filing Date
November 30, 2001

Examiner
To be Assigned

Art Unit
1621

Invention Title

CRYSTALLINE VENLAFAXINE BASE AND
NOVEL POLYMORPHS OF VENLAFAXINE
HYDROCHLORIDE, PROCESSES FOR
PREPARING THEREOF

Inventor(s)

Ben-Zion DOLITZKY et al.

Address to:
Commissioner for Patents
Washington D.C. 20231

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicant hereby bring the following references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.
3. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge Deposit Account No. 11-0600 for such fees. A duplicate copy of this communication is enclosed for charging purposes.

Dated: 6/5/02

By: dk *dk*
Siu K. Lo (Reg. No. 46,877)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on

Date 6/5/02 Atty's Reg. # 46,877

Atty's Signature dk *dk* KENYON & KENYON

KENYON & KENYON
One Broadway
New York, N.Y. 10004
(212) 425-7200 (telephone)